Last reviewed · How we verify
SR57667B
At a glance
| Generic name | SR57667B |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease (PHASE2)
- Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease (PHASE2)
- Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease (PHASE2)
- Study of the Effect of SR57667B in Patients With Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SR57667B CI brief — competitive landscape report
- SR57667B updates RSS · CI watch RSS
- Sanofi portfolio CI